Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.72 |
| ▸ | CA1 | P00915 | 6/20 | 0.72 |
| ▸ | CA2 | P00918 | 6/20 | 0.72 |
| ▸ | CA7 | P43166 | 6/20 | 0.72 |
| ▸ | CA9 | Q16790 | 6/20 | 0.72 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.72 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 2/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30812164 | 0.86 | ESR1 (0.72) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2543424 | 0.86 | ESR1 (0.72) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22468902 | 0.86 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23304948 | 0.85 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL137202 | 0.84 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31700926 | 0.84 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL39791 | 0.84 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29625511 | 0.84 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10487727 | 0.83 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL277473 | 0.83 | CA12 (0.57) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522597-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| CN-119638696-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4463451-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | Rezubio Pharmaceuticals Co., Ltd (CN) | 2024-11-20 | — | — | EP | disclosed |
| CN-114634512-B | Compounds as inhibitors of bruton's tyrosine kinase, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023134712-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | WO | disclosed |
| CN-116102449-A | Phenyl derivatives as cannabinoid receptor 2 agonists | 豪夫迈·罗氏有限公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2023025277-A1 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-03-02 | — | — | WO | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| CN-108349901-B | Phenyl derivatives as cannabinoid receptor 2 agonists | 豪夫迈·罗氏有限公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20070129354-A1 | Biphenyl carboxylic amide p38 kinase inhibitors | GLAXOSMITHKLINE LLC | 2007-06-07 | — | — | US | disclosed |
| US-20070129354-A1 | Biphenyl carboxylic amide p38 kinase inhibitors | GLAXOSMITHKLINE LLC | 2007-06-07 | — | — | US | disclosed |
| WO-2006093832-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-7053071-B2 | For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells | THE BURNHAM INSTITUTE (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1608616-A1 | BIPHENYL CARBOXYLIC AMIDE P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004089874-A1 | BIPHENYL CARBOXYLIC AMIDE P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-1456165-A1 | INDUCTION OF APOPTOSIS IN CANCER CELLS | The Burnham Institute (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030176506-A1 | Induction of apoptosis in cancer cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2003-09-18 | — | — | US | disclosed |
| WO-2003048101-A1 | INDUCTION OF APOPTOSIS IN CANCER CELLS | THE BURNHAM INSTITUTE (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129354-A1 | Biphenyl carboxylic amide p38 kinase inhibitors | MAPK1, MAPKAPK2, MAPK7 | CA12 4619/4885CA1 4206/4885CA2 3432/4885 |
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | GPR119, GLP1R, GPR65 | CA12 4146/4885CA1 4770/4885CA2 2023/4885 |
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | CA12 4054/4885CA1 876/4885CA2 277/4885 |
| US-20030176506-A1 | Induction of apoptosis in cancer cells | MCL1, BAD, BCL2 | CA12 2413/4885CA1 1420/4885CA2 1987/4885 |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | CA12 4864/4885CA1 4843/4885CA2 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.